Neurology Medical News about SUNCT syndrome; methylprednisolone therapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Methylprednisolone therapy for short-term prevention of SUNCT syndrome
Cephalalgia, 08/11/09

Trauninger A et al. – Short–lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is characterized by severe and frequent daily pain attacks causing transient physical disability for the patients during the headache period. Currently there is no option for abortive treatment of the attacks, mainly due to the short–lived nature and frequency of the repeated headaches, while highly efficacious therapy is also unavailable for short–term prevention. The authors report rapidly suppressed headache attacks with orally administered methylprednisolone in eight headache periods of three patients with idiopathic, episodic SUNCT syndrome. The remission was maintained until the period was over in all cases. Although the mechanism of methylprednisolone action is unclear, it is probably based on the anti–inflammatory effects of the drug.

Exclusive Author Commentary
Zoltan Pfund, 08/11/09

Corticosteroid therapy is an easily available effective treatment in the rare SUNCT syndrome.

<< Previous
Risk factors for postoperative systemic complications in elderly...

Next >>
Headache attributed to intracranial tumours: a prospective cohort...